|
**Overview**: **Dermatophyte Detection RT-PCR Panel****Introduction**: The Dermatophyte Detection RT-PCR Test is a diagnostic tool designed to detect DNA of dermatophytes in skin, nail, or hair samples, facilitating the diagnosis of fungal infections. Associated with tinea infections like athletea's foot or ringworm, these mycotic conditions present with itchy skin, nail changes, and severe complications like chronic infection if untreated, particularly in individuals with compromised immunity or poor hygiene. Per the 2023 American Academy of Dermatology guidelines, the test employs real-time polymerase chain reaction (RT-PCR) technology, delivering results within 3-5 days with high sensitivity and specificity, making it a valuable tool for initial screening in molecular pathology settings. This diagnostic falls under molecular pathology and targets individuals with dermatologic symptoms, addressing the challenge of early detection to guide antifungal therapy or hygiene interventions. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating treatment, and reducing complications. Its multi-sample capability enhances its practicality.**Other Names**: Dermatophyte RT-PCR Test.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2000s by various molecular labs, this test advanced fungal detection by leveraging RT-PCR for rapid DNA identification.**Purpose**: The test detects Trichophyton, Microsporum, and Epidermophyton DNA to guide fungal infection diagnosis, assess dermatologic status, and inform treatment and prevention strategies.**Test Parameters**: Presence of Trichophyton DNA, Microsporum DNA, and Epidermophyton DNA, detected with high specificity to indicate active infection, typically detectable in skin, nail, or hair at elevated levels during active disease.**Pretest Condition**: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report itchy skin, nail changes, or recent fungal exposure.**Specimen**: Skin, nail, hair 10-100 mg, collected with KOH in a sterile container, transported within 24 hours to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling in a cool environment to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not recommended, as freezing may degrade DNA, increasing the risk of false negatives and compromising diagnostic accuracy.**Medical History**: Patients should provide details on itchy skin, nail changes, prior fungal infections, or family history of dermatologic disease, as well as any recent trauma or antifungal use.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated infection including chronicity, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves DNA extraction, RT-PCR amplification, and analysis by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 3-5 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent antifungal use can affect results. Correlation with KOH prep or clinical evaluation is recommended to confirm findings.**Clinical Significance**: A positive result indicates possible dermatophyte infection, necessitating further investigation like KOH prep or dermatology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during early infection.**Specialist Consultation**: Dermatologists should be consulted for case management, treatment planning, and coordination with infectious disease programs.**Additional Supporting Tests**: KOH preparation, fungal culture, or clinical assessment for confirmation.**Test Limitations**: The test may produce false negatives in low fungal load or false positives in contamination, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: AAD Guidelines 2023, Journal of Mycology 2024, Molecular Pathology 2025. |
